Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Alan Pollack, MD, PhD
Advertisement
Articles by Alan Pollack, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From June 2026
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
5